{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:08:49Z","timestamp":1784131729971,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016619","name":"MyoKardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jchf.2019.07.010","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T13:59:28Z","timestamp":1570629568000},"page":"970-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Hyperkalemia and Treatment With RAAS\u00a0Inhibitors During Acute Heart\u00a0Failure Hospitalizations and Their\u00a0Association With Mortality"],"prefix":"10.1016","volume":"7","author":[{"given":"Joost C.","family":"Beusekamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Givertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Ouwerkerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2019.07.010_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.07.010_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.07.010_bib3","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jchf.2019.07.010_bib4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"N\u00fa\u00f1ez","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2019.07.010_bib5","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.07.010_bib6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ejhf.289","article-title":"Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart\u00a0Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergenc","volume":"17","author":"Mebazaa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib8","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.07.010_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jchf.2019.07.010_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib11","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib12","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cardfail.2009.10.025","article-title":"Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect","volume":"16","author":"Weatherley","year":"2010","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.07.010_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacc.2003.06.021","article-title":"What is the optimal serum potassium level in cardiovascular patients?","volume":"43","author":"Macdonald","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.07.010_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/CIRCHEARTFAILURE.117.004644","article-title":"Prognostic significance of creatinine increases during an acute heart failure admission in patients with and without residual congestion","volume":"11","author":"Metra","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib17","first-page":"1","article-title":"ipw: an R package for inverse probability weighting","volume":"43","author":"Wal WM van der","year":"2011","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.jchf.2019.07.010_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCHEARTFAILURE.113.000284","article-title":"Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the placebo-controlled randomized study of the selective a1 adenosine receptor antagonist rolofylline for patients hospitalized","volume":"7","author":"Cleland","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.07.010_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.07.010_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjcard.2016.09.038","article-title":"Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials)","volume":"119","author":"Tromp","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2019.07.010_bib22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.amjcard.2014.12.045","article-title":"Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)","volume":"115","author":"Khan","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2019.07.010_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib24","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program","volume":"50","author":"Desai","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.07.010_bib25","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1097\/CCM.0b013e31818f222b","article-title":"Management of severe hyperkalemia","volume":"36","author":"Weisberg","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jchf.2019.07.010_bib26","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart\u00a0Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib27","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart\u00a0Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.07.010_bib28","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.07.010_bib29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.07.010_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijcard.2008.11.195","article-title":"Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study","volume":"141","author":"Ekundayo","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2019.07.010_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-017-6726-1","article-title":"Identifying subpopulations with distinct response to treatment using plasma biomarkers in acute heart failure: results from the PROTECT trial\u202f: differential response in acute heart failure","volume":"31","author":"Liu","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jchf.2019.07.010_bib32","unstructured":"National Cardiac Audit Programme (NCAP). National Heart Failure Audit: 2016\/17 Summary Report. Available at: https:\/\/www.nicor.org.uk\/wp-content\/uploads\/2018\/11\/Heart-Failure-Summary-Report-2016-17.pdf. Accessed September 5, 2019."}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177919305967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177919305967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:52:19Z","timestamp":1761972739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177919305967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2213177919305967"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2019.07.010","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperkalemia and Treatment With RAAS\u00a0Inhibitors During Acute Heart\u00a0Failure Hospitalizations and Their\u00a0Association With Mortality","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2019.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}